期刊文献+

唑来膦酸、化疗联合多维度协同管理治疗非小细胞肺癌骨转移的疗效及对患者的影响

Influence of Zoledronic Acid,Chemotherapy and Multi-dimensional Collaborative Management on the Treatment Effects for Non-small Cell Lung Cancer Patients with Osseous Metastasis
下载PDF
导出
摘要 目的观察非小细胞肺癌骨转移患者予以多维度协同管理和化疗、唑来膦酸联合干预对其生活质量、疼痛程度、临床效果的影响。方法临床纳入2021年7月至2022年7月河南大学第一附属医院收治的80例非小细胞肺癌骨转移患者,根据随机双盲法分组,分为对照组、研究组,每组均为40例,研究组予以多维度协同管理和化疗、唑来膦酸联合干预,对照组予以多维度协同管理和化疗干预。应用肿瘤患者生存治疗量表分析评估(QLQ-C30)分析两组的生活质量;分析两组的临床效果、心理状况、生活质量、不良反应。结果研究组的临床治疗效果优于对照组,差异有统计学意义(P<0.05)。干预后两组不良心理状态(抑郁、焦虑)指标评分低于干预前,且研究组不良心理(抑郁、焦虑)指标评分低于对照组,差异有统计学意义(P<0.05)。干预后两组肿瘤患者QLQ-C30评分指标均高于干预前,且研究组肿瘤患者QLQ-C30评分指标高于对照组,差异有统计学意义(P<0.05)。治疗后两组不良反应(皮疹、肌痛、发热、恶心呕吐)发生情况比较,差异无统计学意义(P>0.05)。结论非小细胞肺癌骨转移予以多维度协同管理联合化疗、唑来膦酸联合干预可提高患者的心理状态,治疗效果显著,治疗安全性较高,可提高其生活质量,值得临床应用。 Objective To observe the influence of multi-dimensional collaborative management,chemotherapy and zoledronic acid on the life quality,pain degree and treatment effects for non-small cell lung cancer patients with osseous metastasis.Methods A total of 80 non-small cell lung cancer patients with osseous metastasis treated from July 2021 to July 2022 in the First Affiliated Hospital of Henan University were selected.According to random double-blind method,patients were divided into control group and study group,with 40 cases in each group.The study group was given multi-dimensional collaborative management and combined intervention of chemotherapy and zoledronic acid,while the control group was given multi-dimensional collaborative management and chemotherapy intervention.Patient’s life quality was appraised through the quality of life questionnaire core 30(QLQ-C30).Analyze the clinical effects,psychological status,life quality,and adverse reactions of the two groups.Results The clinical effects in the study group were better than control group,with statistically significant difference(P<0.05);after intervention,the adverse mental state scores of depression and anxiety for two groups were remarkably decreased;the adverse mental state scores in the study group were even lower than control group,with statistically significant difference(P<0.05);after treatment,QLQ-C30 scores of social function,emotional function,cognitive function,role physical and physical function for two groups were remarkably increased;QLQ-C30 scores of social function,emotional function,cognitive function,role physical and physical function in the study group were even higher than control group,with statistically significant difference(P<0.05);the incidences of adverse reactions like skin rash,myalgia,fever,nausea and vomiting in the study group were lower than control group,with statistically significant difference(P<0.05).Conclusion The multi-dimensional collaborative management,chemotherapy and zoledronic acid can effectively improve the mental states,treatment effects and safety,and life quality for nonsmall cell lung cancer patients with osseous metastasis.It is worthy of clinical promotion and application.
作者 徐春红 王丹 王峻 张悦华 XU Chunhong;WANG Dan;WANG Jun;ZHANG Yuehua(Department of Pain,the First Affiliated Hospital of Henan University,Kaifeng Henan 475000,China;Department of Fourth Psychiatry,Luoyang Fifth People’s Hospital,Luoyang Henan 471000,China;Department of Equipment,Kaifeng Rehabilitation Hospital,Kaifeng Henan 475000,China;Department of Oncology,First Affiliated Hospital of Henan University,Kaifeng Henan 475000,China)
出处 《临床研究》 2023年第7期69-72,共4页 Clinical Research
基金 河南省医学科技攻关计划(联合共建)项目(LHGJ20190500)。
关键词 生活质量 疼痛程度 骨转移 非小细胞肺癌 多维度协同管理 唑来膦酸 life quality pain degree osseous metastasis non-small cell lung cancer multi-dimensional collaborative management zoledronic acid
  • 相关文献

参考文献11

二级参考文献88

  • 1徐国柱,蔡志基.镇痛药临床评价方法研究[J].中国新药杂志,1995,4(4):20-22. 被引量:256
  • 2万崇华,杨铮,孟琼,汤学良,卢玉波,邹天宁,张冬梅.乳腺癌患者生命质量测定量表QLQ-BR53中文版的应用评价[J].肿瘤,2006,26(2):184-187. 被引量:73
  • 3Kodo O, Sabokbar A, Itonaga I, et al. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism[J]. Bone,2003,32 (1): 1-7.
  • 4Siwik D A, Chang D L, Colucci W S. Interliukin-1β and tumor necrosis factor-αdecrease collagen synthesis and increase matrix metalloproteinase activity in cardiac fibroblasts in vitro [J]. Circ Res, 2000, 86 (12): 1259-1265.
  • 5Major P P, Cook R. Efficacy of bishposphonates in the management of skeletal complications of bone metastases and selection of clinical end points[J]. Am J Clin Oncol, 2002,25 (Suppl 1): 10-18.
  • 6Rosen L S, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma[J].Cancer,2003,98: 1735-1744.
  • 7Zhao M, Tominaga Y, Ohuchida K, et al. Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer [J]. Cancer Sci,2012,103 (1): 58-66.
  • 8Lee S R, Gordon D H, Dugan W, et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at lest one steolytic lesion[J]. Cancer,2004,100(1): 36-43.
  • 9Ziebart T, Pabst A, Klein M O, et al. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro[J]. Clin Oral Investig,2011,15(1):105-111.
  • 10Choudhury K B, Mallik C, Sharma S,et al. A randomized controlled trial to compare the efficacy of bisphosphonates in the management of painful bone metastasis[J].Indian J Palliat Care,2011,17(3):210-218.

共引文献103

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部